主管单位:中华人民共和国
国家卫生健康委员会
主办单位:
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
英文作者:Li Yang1 Liu Yan1 Su Pixiong1 An Xiangguang1 Gu Song1 Yang Suqiao2
单位:1首都医科大学附属北京朝阳医院心脏中心高血压病研究北京市重点实验室100020;2首都医科大学附属北京朝阳医院呼吸内科100020
英文单位:1Heart Center and Beijing Key Laboratory of Hypertension Beijing Chao-yang Hospital Capital Medical University Beijing 100020 China; 2Department of Respiratory Medicine Beijing Chao-yang Hospital Capital Medical University Beijing 100020 China
英文关键词:Chronicthromboembolicpulmonaryhypertension;Percutaneousballoonpulmonaryangioplasty
慢性血栓栓塞性肺动脉高压(CTEPH)是一类肺动脉梗阻性疾病,其病因较复杂,主要为血栓栓塞导致肺动脉堵塞,肺部血管结构改变,进而产生肺动脉高压。肺动脉内膜剥脱术是CTEPH的首选治疗方法。随着介入治疗的发展,经皮球囊肺动脉成形术逐渐成为无法行肺动脉内膜剥脱术、术后仍持续肺动脉高压或复发患者的一种新选择。本文对经皮球囊肺动脉成形术治疗CTEPH的研究进展进行综述。
Chronic thromboembolic pulmonary hypertension (CTEPH) is a group of pulmonary artery obstructive disease. The pathogeny is complex, mainly due to pulmonary artery blockage caused by thromboembolism, changes in pulmonaty vascular structure, and then leads to pulmonary hypertension (PH). The primary treatment for CTEPH is pulmonary endarterectomy (PEA). For patients ineligible for PEA or have recurrent or persistent PH after surgery, percutaneous balloon pulmonary angioplasty (BPA) is an emerging option with the development of interventional treatment. This article reviews the research progress on BPA in the treatment of CTEPH.
copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。